Compare Sterling Biotech with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs AJANTA PHARMA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH AJANTA PHARMA STERLING BIOTECH/
AJANTA PHARMA
 
P/E (TTM) x -0.4 22.4 - View Chart
P/BV x 0.0 3.9 0.4% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 STERLING BIOTECH   AJANTA PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
AJANTA PHARMA
Mar-19
STERLING BIOTECH/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs111,422 0.7%   
Low Rs3898 0.4%   
Sales per share (Unadj.) Rs26.8233.5 11.5%  
Earnings per share (Unadj.) Rs-15.044.0 -34.0%  
Cash flow per share (Unadj.) Rs-5.552.2 -10.5%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs54.9255.1 21.5%  
Shares outstanding (eoy) m267.8788.02 304.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.35.0 5.2%   
Avg P/E ratio x-0.526.4 -1.8%  
P/CF ratio (eoy) x-1.322.2 -5.7%  
Price / Book Value ratio x0.14.5 2.8%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m1,862102,081 1.8%   
No. of employees `0001.46.8 19.9%   
Total wages/salary Rs m5474,307 12.7%   
Avg. sales/employee Rs Th5,303.33,022.6 175.5%   
Avg. wages/employee Rs Th403.8633.4 63.8%   
Avg. net profit/employee Rs Th-2,959.0569.1 -520.0%   
INCOME DATA
Net Sales Rs m7,18120,554 34.9%  
Other income Rs m43211 20.2%   
Total revenues Rs m7,22320,765 34.8%   
Gross profit Rs m9475,664 16.7%  
Depreciation Rs m2,543721 352.8%   
Interest Rs m4,37712 37,733.6%   
Profit before tax Rs m-5,9315,143 -115.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,273 -151.2%   
Profit after tax Rs m-4,0073,870 -103.5%  
Gross profit margin %13.227.6 47.8%  
Effective tax rate %32.424.8 131.1%   
Net profit margin %-55.818.8 -296.4%  
BALANCE SHEET DATA
Current assets Rs m14,33511,812 121.4%   
Current liabilities Rs m49,8093,776 1,319.0%   
Net working cap to sales %-494.039.1 -1,263.6%  
Current ratio x0.33.1 9.2%  
Inventory Days Days40377 521.3%  
Debtors Days Days17182 209.1%  
Net fixed assets Rs m55,43214,398 385.0%   
Share capital Rs m268175 152.7%   
"Free" reserves Rs m13,93522,277 62.6%   
Net worth Rs m14,70122,452 65.5%   
Long term debt Rs m9,4787 143,603.8%   
Total assets Rs m73,98826,962 274.4%  
Interest coverage x-0.4444.3 -0.1%   
Debt to equity ratio x0.60 219,315.3%  
Sales to assets ratio x0.10.8 12.7%   
Return on assets %0.514.4 3.5%  
Return on equity %-27.317.2 -158.1%  
Return on capital %-6.423.0 -28.0%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86010,682 17.4%   
Fx outflow Rs m252,102 1.2%   
Net fx Rs m1,8358,580 21.4%   
CASH FLOW
From Operations Rs m1,7193,748 45.9%  
From Investments Rs m-3,148-2,228 141.3%  
From Financial Activity Rs m1,426-1,475 -96.7%  
Net Cashflow Rs m-345 -7.5%  

Share Holding

Indian Promoters % 33.9 73.8 45.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.6 -  
FIIs % 9.9 7.6 130.3%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 17.0 231.2%  
Shareholders   21,482 20,968 102.5%  
Pledged promoter(s) holding % 55.9 4.4 1,274.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Auto and Energy Stocks Witness Buying(Closing)

Indian share markets ended their volatile trading day on a flattish note. At the closing bell, the BSE Sensex stood higher by 42 points (up 0.1%).

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

This PSU Turned into a Rare 100 Bagger. Others May Follow.(The 5 Minute Wrapup)

Nov 27, 2019

The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS